#United States #Bellevue #Peripheral Artery Disease #Vasa Therapeutics #VS-214

Vasa Therapeutics to Present Insights on VS-214 at AHA Meeting

Vasa Therapeutics, a pioneering company in biotechnology focused on developing revolutionary therapies for cardiovascular conditions, has revealed exciting news regarding its drug candidate VS-214. Selected for an oral presentation at the 2026 Vascular Discovery From Genes to Medicine Scientific Sessions hosted by the American Heart Association, this study shines a light on the potential of VS-214 as a groundbreaking treatment for Peripheral Artery Disease (PAD).

Key Presentation Details

The oral presentation is scheduled for May 14, 2026, during the Concurrent Session dedicated to peripheral arterial disease, aortic aneurysm, and cerebrovascular issues. Vasa's CEO, Dr. Artur Plonowski, will deliver the presentation, emphasizing the significant findings from the company’s research. This session will occur from 10:30 AM to 12:00 PM at the Regency Ballroom in the Hyatt Regency Bellevue, Washington.

Exciting Developments in Vascular Medicine

Dr. Plonowski has expressed optimism about the potential of apelin biology in vascular medicine, pointing out that their studies indicate that VS-214, a long-acting apelin agonist, could enhance limb blood flow and improve walking capacity for patients suffering from PAD. This offers a new pharmacological approach comparable to supervised exercise therapy, which is recognized as an effective intervention for symptomatic PAD.

The prevalence of PAD affects 10 to 12 million individuals in the United States, with incidence rising alongside age and common risk factors such as smoking, hypertension, and diabetes. With approximately 400 limb amputations occurring daily due to this condition, the urgency for effective pharmacological treatments cannot be stressed enough. Currently, there are no significant medical interventions available to address the symptoms of PAD, highlighting the unmet medical needs in this field.

Innovating Treatments for Unmet Needs

The development and eventual approval of VS-214 holds promising implications for addressing the challenges posed by PAD. As a long-acting peptide analog designed to facilitate neovascularization, VS-214 aims to enhance limb perfusion and restore crucial muscle endurance in patients. By mimicking the response of supervised exercise therapy, Vasa Therapeutics hopes to set a new standard in treating this debilitating condition, which considerably impacts patient quality of life.

The upcoming presentation at the Vascular Discovery meeting reflects the innovative nature of Vasa's research. It not only acknowledges the scientific significance of the VS-214 program but also reinforces the company's commitment to addressing critical medical needs through unique therapeutic approaches.

About Vasa Therapeutics

Vasa Therapeutics is dedicated to discovering first-in-class therapeutic options for patients facing cardiovascular, neuromuscular, and age-related health challenges. By leveraging mechanisms integral to cardiovascular health, the company strives to provide therapies that positively influence patients' lives and offer durable outcomes. Vasa's pipeline includes various targeted therapies exemplifying the potential for impactful innovation in treating serious conditions.

Located in Encinitas, California, Vasa is at the forefront of developing advanced medical solutions, with VS-214 being a testament to its valuable contributions to contemporary medicine. As the healthcare community eagerly anticipates further information from the Vascular Discovery meeting, Vasa Therapeutics prepares to unveil findings poised to change the landscape of PAD treatment.

To learn more about Vasa Therapeutics and the ongoing research efforts, visit Vasa Therapeutics.